HELP PATIENTS
SELF-INFUSE WITH CONFIDENCE
Infusion Resources & Training
Infusion resources and tips to help patients gain comfort with Hizentra
Explore essential resources to support patients throughout the infusion process
Infusion Support for Clinicians
CSL Behring provides healthcare providers with insight, information, and 1:1 training regarding the administration of Hizentra.
Self-Infusion Training Certification
This certification is intended for clinicians to become proficient in educating patients on the self-infusion process. It is provided through the S.H.A.R.E. Training program (Starting Hizentra Administration with Resources and Education).
Locate Self-Infusion Training Experts
Explore our online locator of clinicians who are experts in teaching patients how to self-infuse Hizentra. These healthcare professionals have completed our S.H.A.R.E. Training program (Starting Hizentra Administration with Resources and Education).
Frequently Asked Questions
More information about helping patients get started on Hizentra may be found in our FAQ section.
HCP and Patient Support Program
Hizentra Connect℠ provides comprehensive support for you and your patients. Exclusive resources include:
- In-home nurse training for patients
- Access to a network of specially trained nurses for healthcare providers
- A free trial with a month’s supply of product
- Reimbursement support for your office
Self-Infusion Resources for Your Patients
Proper self-infusion training from the start can help patients avoid issues going forward. Helpful resources include:
- Welcome kit for new patients
- Informative brochures
- Step-by-step training video
- Hizentra app to track infusions and more
Best practices
Considerations for infusion optimization
- Store Hizentra properly: it should be stored at room temperature (up to 25°C [77°F]) protected from light. No refrigeration required
- If your patient has skin sensitivities to tape/adhesive, consider alternative methods to secure the needles in place
- A cold pack or topical anesthetic may be applied before needle insertion to increase comfort
- Ensure pump settings match infusion rate
- Tubing size/length must also match infusion rate
- Choose a needle gauge consistent with the volume being infused
- Common SC needle gauges include 24, 26, and 27
- Choose a needle length that penetrates subcutaneous tissue but not muscle or intradermal tissues
- Common SC needle lengths (mm) include 4, 6, 9, 12, and 14
- Ensure needle is affixed securely and fully inserted without potential for movement
- Ensure there are no drops of Ig on needle prior to insertion (dry prime)
Select infusion sites:
- With appropriate amount of subcutaneous tissue (abdomen, thigh, upper arm, or side of upper leg/hip)
- That support optimal patient tolerability and comfort (rotate sites with each infusion)
- That do not promote needle movement during infusion
Infusion sites should be at least 2 inches apart and at least 1 inch from a previous infusion site. Never infuse into areas where the skin is tender, bruised, red, or hard. Avoid infusing into scars or stretch marks.
Monitor patient tolerability and adjust, as needed*:
- Total volume infused per site
- Rate of infusion
- Infusion site location
- Needle length
*For the first infusion of Hizentra, do not exceed a volume of 15 mL/site or a flow rate of 15 mL/h/site. For subsequent infusions, the volume per site and flow rate may be increased to 25 mL/site and 25 mL/h/site respectively, as tolerated.
Committed to access and affordability
National commercial coverage6†
Most patients with commercial insurance pay $0‡
†As of July 2025. Prior authorization or step therapy may be required.6
‡Subject to terms and conditions of the Copay Support Program. The Copay Support Program provides eligible Hizentra patients with commercial insurance up to $20,000 in copay assistance per calendar year.
Abbreviations: HCP, healthcare provider; SC, subcutaneous.
References: 1. Watkins JM, Dimachkie MM, Riley P, Murphy E. J Neurosci Nurs. 2019;51(4):198-203. doi:10.1097/JNN.0000000000000451 2. Radley E, Hendricks L, Barrett L, Murphy E, Sivamurthy K. Real-world experience of needle length use based on BMI for IgPro20 administration. Poster P104 presented at: Immunoglobulin National Society (IgNS); 2023 Oct 5-8; Denver, CO. 3. Freedom60® Infusion System Instructions for Use. KORU Medical Systems. 2023. 4. FreedomEdge® Syringe Infusion System Instructions for Use. KORU Medical Systems. 2023. 5. SCIg60 Infusion System Instructions for Use. EMED Technologies; AS-0010021_2.0. 6. Data on File. Available from CSL Behring as DOF HIZ-019.
IMPORTANT SAFETY INFORMATION
WARNING: Thrombosis may occur with immune globulin products, including Hizentra. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.
For patients at risk of thrombosis, administer Hizentra at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Hizentra is contraindicated in patients with a history of anaphylactic or severe systemic reaction to human immune globulin (Ig) or components of Hizentra (eg, polysorbate 80), as well as in patients with immunoglobulin A deficiency with antibodies against IgA and a history of hypersensitivity. Because Hizentra contains L-proline as stabilizer, use in patients with hyperprolinemia is contraindicated.
IgA-deficient patients with anti-IgA antibodies are at greater risk of severe hypersensitivity and anaphylactic reactions. Thrombosis may occur following treatment with Ig products, including Hizentra.
Monitor patients for aseptic meningitis syndrome (AMS), which may occur following treatment with Ig products, including Hizentra. In patients at risk of acute renal failure, monitor renal function, including blood urea nitrogen, serum creatinine and urine output. In addition, monitor patients for clinical signs of hemolysis or pulmonary adverse reactions (eg, transfusion-related acute lung injury [TRALI]).
Hizentra is derived from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.
The most common adverse reactions (observed in ≥5% of study subjects) were local infusion-site reactions, as well as headache, diarrhea, fatigue, back pain, nausea, extremity pain, cough, upper respiratory tract infection, rash, pruritus, vomiting, upper abdominal pain, migraine, arthralgia, pain, fall, and nasopharyngitis.
The passive transfer of antibodies can interfere with response to live virus vaccines and lead to misinterpretation of serologic test results.
Indications
Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, is indicated for:
- Treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years and older.
- Maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.
- Limitation of Use: Maintenance therapy in CIDP has been systematically studied for 6 months and for a further 12 months in a follow-up study. Continued maintenance beyond these periods should be individualized based on patient response and need for continued therapy.
For subcutaneous infusion only.
Please see full Prescribing Information for Hizentra including boxed warning.
To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® is a registered trademark of CSL Behring AG.
Hizentra Connect℠ is a service mark of CSL Behring LLC.